{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:53:08Z","timestamp":1774536788884,"version":"3.50.1"},"reference-count":0,"publisher":"Ideggyogyaszati Szemle Journal","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ideggy\u00f3gy\u00e1szati szemle"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Az anti-CD20 molekul\u00e1k hat\u00e9konys\u00e1ga sclerosis multiplexben (SM) 2008 \u00f3ta ismert. Ezt k\u00f6vet\u0151en h\u00e1rom anti-CD20 molekula \u2013 ocrelizumab, ofatumumab, ublituximab \u2013 ker\u00fclt bevezet\u00e9sre, m\u00edg a hat\u00e9konys\u00e1got jelz\u0151 legels\u0151 molekula, a rituximab, off-label SM-ter\u00e1pia. Az anti-CD20 ellenanyagok B-sejt-deplet\u00e1l\u00f3 hat\u00e1sa k\u00e9t f\u0151 mechanizmussal, a komplementrendszer \u00e9s az NK-sejtek \u00e1ltal medi\u00e1lt citotoxicit\u00e1ssal zajlik. E k\u00e9t mechanizmus hat\u00e9konys\u00e1ga elt\u00e9r\u0151 az egyes anti-CD20 ellenanyagok eset\u00e9ben. A hat\u00e9konys\u00e1got befoly\u00e1solja az anti-CD20 ellenanyagok Fc-r\u00e9gi\u00f3j\u00e1nak glikozil\u00e1ci\u00f3ja \u00e9s az Fc\u03b3RIIIa-receptort k\u00f3dol\u00f3 g\u00e9nek polimorfizmusa is, mivel az ellenanyag Fc-r\u00e9gi\u00f3ja ezen a receptoron kereszt\u00fcl aktiv\u00e1lja az NK-sejteket. Az Fc-r\u00e9gi\u00f3 tervez\u00e9s\u00e9vel a NK-sejtek \u00e1ltal medi\u00e1lt citotoxicit\u00e1s hat\u00e9konys\u00e1ga n\u00f6velhet\u0151, \u00e9s az Fc\u03b3RIIIa polimorfizmus hat\u00e1sa kompenz\u00e1lhat\u00f3. A k\u00f6zlem\u00e9ny \u00f6sszefoglalja az immunglobulinok \u00e9s az anti-CD20 ellenanyagok szerkezet\u00e9t \u00e9s m\u0171k\u00f6d\u00e9s\u00e9t, az anti-CD20 molekul\u00e1k hat\u00e9konys\u00e1g\u00e1nak \u00e9s tolerabilit\u00e1s\u00e1nak fokoz\u00e1s\u00e1t szolg\u00e1l\u00f3 humaniz\u00e1l\u00e1s \u00e9s Fc-r\u00e9gi\u00f3tervez\u00e9s folyamat\u00e1t, az ublituximab klinikai vizsg\u00e1latainak eredm\u00e9nyeit, valamint kitekint\u00e9st ny\u00fajt a B-sejtdepletio egy\u00e9b lehet\u0151s\u00e9geire is.<\/jats:p>","DOI":"10.18071\/isz.79.0131","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:58:41Z","timestamp":1774533521000},"page":"131-141","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD20-tervez\u00e9s \u00e9s B-sejt-depleti\u00f3s mechanizmusok sclerosis muliplexben"],"prefix":"10.18071","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-0450","authenticated-orcid":false,"given":"Zsolt","family":"Ill\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7411","published-online":{"date-parts":[[2026]]},"container-title":["Ideggy\u00f3gy\u00e1szati szemle"],"original-title":[],"link":[{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/developing-anti-cd20-molecules-and-b-cell-depletion-in-multiple-sclerosis\/pdf-open","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:58:43Z","timestamp":1774533523000},"score":1,"resource":{"primary":{"URL":"https:\/\/elitmed.hu\/en\/publications\/clinical-neuroscience\/developing-anti-cd20-molecules-and-b-cell-depletion-in-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":0,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2026]]},"published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.18071\/isz.79.0131","relation":{},"ISSN":["0019-1442","2498-6208"],"issn-type":[{"value":"0019-1442","type":"print"},{"value":"2498-6208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}